- Clinical Pharmacology
- Indications & Usage
- Side Effects
- Dosage & Administration
- How Supplied
- Patient Counseling Information
- Supplemental Patient Material
- Boxed Warning
- Patient Package Insert
FULL PRESCRIBING INFORMATION: CONTENTS*
- DOSAGE AND ADMINISTRATION:
- ANIMAL SAFETY:
- STORAGE CONDITIONS:
- HOW SUPPLIED:
FULL PRESCRIBING INFORMATION
Brand of Polysulfated Glycosaminoglycan (PSGAG)
Solution 500 mg/5 mL
For Intramuscular Use In Horses
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Each 5 milliliters of Adequan® i.m. contains 500 mg of Polysulfated Glycosaminoglycan and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. Sodium Chloride may be added to adjust tonicity.
Polysulfated Glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components. PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration in traumatized equine carpal and hock joints.
Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
DOSAGE AND ADMINISTRATION:
The recommended dose of Adequan® i.m. in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan® i.m. with other drugs or solvents.
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.
Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children.
The safe use of Adequan® i.m. in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.
Toxicity studies were conducted in horses. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal had any clinical or laboratory evidence of toxicity.
Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature). Discard unused portion. Dispose of spent needles in accordance with all federal, state and local environmental laws.
Adequan® i.m. solution, 500 mg/5 mL is available in 5 mL glass vials, packaged in boxes of 7.
LUITPOLD PHARMACEUTICALS, INC.
Animal Health Division
Shirley, NY 11967
Made in U.S.A.
NADA #140-901, Approved by FDA
PRINCIPAL DISPLAY PANEL – 5 mL Carton
Adequan ® i.m.
SINGLE DOSE VIALS
7 Vials (5 mL each)
For intramuscular use in horses
- For the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.
A Division of Luitpold Pharmaceuticals, Inc.
polysulfated glycosaminoglycan INJECTION, SOLUTION